Erythrocyte-Like Mesoporous PDA@CeO Nanozyme with Dual Drugs for Periodontitis Treatment.

Periodontitis is a chronic oral inflammatory disease with the characteristic of excess oxidative stress in the inflammatory site, dramatically decreasing the quality of life. Studies show that nanozymes can be ideal candidates for ROS scavenging in periodontitis. Here, we design a multipath anti-inflammatory mesoporous polydopamine@cerium oxide nanobowl (mPDA@CeO NB) with multienzyme mimicking properties, which combines the advantages of both CeO NP and mPDA NB for synergistically eliminating reactive oxygen species (ROS), including hydroxyl radical (OH), hydrogen peroxide (HO), and superoxide (O). Besides, the erythrocyte-like structure of mNBs makes them a facility for cell uptake, and the mesopores can load both hydrophobic and hydrophilic drugs for combined anti-inflammatory therapy. In vitro and in vivo experiments prove that the combination of CeO and mPDA can synergistically achieve multiple complementary ROS eliminations and suppression of ROS-induced inflammation. Moreover, the ROS regulation plus anti-inflammatory drugs in one mPDA@CeO NB prevents the progression of periodontitis in a mouse model. Therefore, the design of mPDA@CeO NB with these excellent properties provides a therapeutic strategy for inflammatory diseases.